A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of divarasib compared to
locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS
G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Age: 18 years - 66+
Gender: All
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
The goal of this study is to evaluate V940 plus pembrolizumab versus placebo plus
pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage
II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The
primary hypot...
Age: 18 years - 66+
Gender: All
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and
paclitaxel combination therapy in patients with relapsed or refractory extensive stage small
cell lung cancer.
Age: 18 years - 66+
Gender: All
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
This study is researching an investigational drug called fianlimab (also called REGN3767)
with two other medications called cemiplimab and chemotherapy, individually called a
"study drug" or collectively called "study drugs". 'Investigational' means that the study
dr...
Age: 18 years - 66+
Gender: All
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection)
given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab
given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial
an...
Age: 18 years - 66+
Gender: All
GEMINI-NSCLC: NSCLC Biomarker Study
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goa...
Age: 18 years - 66+
Gender: All
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of
BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib...
Age: 18 years - 66+
Gender: All
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2
study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Age: 18 - 70 years
Gender: All
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study
of BT8009 given as a single agent and in combination with pembrolizumab in participants
with advanced solid tumors associated with Nectin-4 expression or in participants with
ad...
Age: 18 years - 66+
Gender: All
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs.
osimertinib alone for the treatment of non-small cell lung cancer that has spread outside
of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR
...
Age: 18 years - 66+
Gender: All
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed
by pemetrexed and carboplatin with or without pembrolizumab after disease progression is
superior to induction with pembrolizumab, pemetrexed and carboplatin followed by
p...
Age: 18 years - 66+
Gender: All
Collection of Sputum and Labeling for Lung Cancer
The primary objective of this study is to compare Assay results to diagnoses determined by
currently accepted standards for lung cancer detection. This will be accomplished by analysis
of sputum samples from three cohorts including healthy Participants, high risk Pa...
Age: 21 years - 66+
Gender: All